Company Name or Ticker Symbol
Search for other Categories
Lexaria Bioscience Corp.  (LXRP)
Other Ticker:  
    Sector  Consumer Non Cyclical    Industry Legal Marijuana
Price: $1.5900 $-0.01 -0.625%
Day's High: $ 1.61 Week Perf: -6.74 %
Day's Low: $ 1.53 30 Day Perf: 1.92 %
Volume (M): 160 52 Wk High: $ 2.54
Volume (M$): $ 254 52 Wk Avg: $ 0.69
Open: 1.54 52 Wk Low: 0.27
  LXRP Charts & Quotes
You need to upgrade your Flash Player

 Market Capitalization (Millions $) 109
 Shares Outstanding (Millions) 69
 Employees 4
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0
Lexaria Bioscience Corp.
Our company’s business plan is currently focused on the development of strategic partnerships with licensees for our patented technology in exchange for up front and/or staged licensing fees over time. Secondarily and more generally, we continue to investigate national and international opportunities for development and distribution of the Company’s enhanced functional food and supplement product offerings; to investigate expansions and additions to our intellectual property portfolio; and, to search for additional opportunities in alternative health sectors. This includes the acquisition or development of intellectual property if and when we believe it advisable to do so. We announced issuance of our first patent by the U.S. Patent and Trademark Office (USPTO) on October 26, 2016 and have received a Notice of Acceptance from the Australian Patent Office with related patent issuance date June 15 2017 No. 2015274698. We announced on November 2, 2017 a new Notice of Allowance from the USPTO that included the delivery of additional molecules such as psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatories, and nicotine all utilizing our DehydraTECHTM delivery technology. We are seeking additional patent protection for what we believe to be a unique process for the nutritional delivery of certain molecules such as cannabinoids, Nicotine, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Vitamins. To achieve sustainable and profitable growth, our company intends to control the timing and costs of our projects wherever possible.


Lexaria Bioscience's Segments
  Company Estimates  
  Revenue Outlook
Lexaria Bioscience does not provide revenue guidance.

Earnings Outlook
Lexaria Bioscience Corp. does not provide earnings estimates.

Geographic Revenue Dispersion

Bemis Co Inc

Forth quarter Profits vanish on impairment charges

Bemis Co Inc revalues it's goodwill and intangible assets, by taking $196.60 million charge in the forth quarter

Aflac Inc

A $2,169.00 million tax benefit, helped Aflac Inc to post $6.54 eps in the forth quarter, company lowers it's earnings outlook.

A $2,169.00 million tax benefit, helped Aflac Inc to post $6.54 eps in the forth quarter

LXRP's Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 108.39
Price to Sales (Expected) -
Price to Book 45.44
LXRP's Financial Strength Current
Quick Ratio 23.09
Working Capital Ratio 25.26
Leverage Ratio (MRQ) 0.04
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -
Per Share Current
Earnings (TTM) -0.04 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) 0.03 $
Cash 0.03 $
Book Value 0.03 $
Dividend (TTM) 0 $

• View Valuation Comparisons • View Growth Rates Comparisons

You need to upgrade your Flash Player
LXRP's Efficiency Current
Revenue per Employee (TTM) 251,714
Net Income per Employee (TTM) -499,366
Receivable Turnover Ratio (TTM) 20.32
Inventory Turnover Ratio (TTM) 9.25
Asset Turnover Ratio (TTM) 0.44
LXRP's Profitability Ratio Current
Gross Margin 75.24 %
Operating Margin -
Net Margin -
Net Cash Flow Margin -
Effective Tax Rate (TTM) -
Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Payout Ratio (TTM) -
• View Efficiency Comparisons • View Profitability Comparisons • View Management Effectiveness

You need to upgrade your Flash Player

You need to upgrade your Flash Player
Major Competitors Stock performance

5 Days Decrease / Increase
• View Complete Report


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

QUAD's Profile

Stock Price

QUAD's Financials

QUAD's Expectations

Business Description


Charts & Quotes

QUAD's News


QUAD's Competitors

Customers & Markets

Economic Indicators

QUAD's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength



Management Effectivness


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries





At a Glance








About us

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com